Prognostic significance of osteopontin expression in non-small-cell lung cancer: A meta-analysis

Zou,Xue‑Lin; Wang,Chun; Liu,Ke; Nie,Wen; Ding,Zhen‑Yu

doi:10.3892/mco.2015.517

Prognostic significance of osteopontin expression in non-small-cell lung cancer: A meta-analysis

Authors:
- Xue‑Lin Zou
- Chun Wang
- Ke Liu
- Wen Nie
- Zhen‑Yu Ding
View Affiliations

Affiliations: Division of Thoracic Cancer, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Endocrinology, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Occupational Health and Radiological Health, Zigong Center for Disease Control and Prevention, Zigong, Sichuan 643000, P.R. China, School of Clinical Medicine, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: February 26, 2015 https://doi.org/10.3892/mco.2015.517
Pages: 633-638

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteopontin (OPN) plays an important role in the progression and metastasis of cancer. However, the role of OPN as a prognostic factor in non‑small‑cell lung cancer (NSCLC) remains controversial. The aim of this study was to investigate the association between OPN expression and prognosis in patients with NSCLC using a meta‑analysis. Based on PubMed, Ovid Medline, Embase, ISI, ScienceDirect and SpringerLink databases, related articles published prior to January, 2013 were collected. A meta‑analysis was conducted to investigate the association of OPN expression with overall survival (OS) and progression‑free survival (PFS) in patients with NSCLC. Hazard ratio (HR) with 95% confidence interval (CI) was used to assess the strength of this association. A total of 6 studies, including 776 patients, were found to be eligible for the meta‑analysis. No heterogeneity was observed in OS or PFS, whereas low OPN expression was found to be correlated with better OS (HR=0.57, 95% CI: 0.46‑0.70) and PFS (HR=0.62, 95% CI: 0.49‑0.77). This meta‑analysis demonstrated an association of OPN with poor prognosis in NSCLC patients. However, prospective studies are required to confirm these findings.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Spiro SG and Silvestri GA: One hundred years of lung cancer. Am J Respir Crit Care Med. 172:523–529. 2005. View Article : Google Scholar : PubMed/NCBI
3	Zheng Z, Chen T, Li X, Haura E, Sharma A and Bepler G: DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 356:800–808. 2007. View Article : Google Scholar : PubMed/NCBI
4	Denhardt DT and Guo X: Osteopontin: a protein with diverse functions. FASEB J. 7:1475–1482. 1993.PubMed/NCBI
5	Shijubo N, Kojima H, Nagata M, Ohchi T, Suzuki A, Abe S and Sato N: Tumor angiogenesis of non-small cell lung cancer. Microsc Res Tech. 60:186–198. 2003. View Article : Google Scholar : PubMed/NCBI
6	O'Regan A: The role of osteopontin in lung disease. Cytokine Growth Factor Rev. 14:479–488. 2003. View Article : Google Scholar : PubMed/NCBI
7	Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF and Casson AG: Osteopontin expression in lung cancer. Lung Cancer. 15:311–323. 1996. View Article : Google Scholar : PubMed/NCBI
8	Tierney JF, Stewart LA, Ghersi D, Burdett S and Sydes MR: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
9	Whitehead A and Whitehead J: A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med. 10:1665–1677. 1991. View Article : Google Scholar : PubMed/NCBI
10	Ioannidis JP, Patsopoulos NA and Evangelou E: Uncertainty in heterogeneity estimates in meta-analyses. BMJ. 335:914–916. 2007. View Article : Google Scholar : PubMed/NCBI
11	Higgins JP, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ. 327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
12	DerSimonian R and Laird N: Meta-analysis in clinical trials. Control Clin Trials. 7:177–188. 1986. View Article : Google Scholar : PubMed/NCBI
13	Mantel N and Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:719–748. 1959.PubMed/NCBI
14	Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
15	Macaskill P, Walter SD and Irwig L: A comparison of methods to detect publication bias in meta-analysis. Stat Med. 20:641–654. 2001. View Article : Google Scholar : PubMed/NCBI
16	Weber GF, Lett GS and Haubein NC: Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer. 103:861–869. 2010. View Article : Google Scholar : PubMed/NCBI
17	Zhang L, Hou X, Lu S, et al: Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: a large cohort retrospective study. Lung Cancer. 67:114–119. 2010. View Article : Google Scholar : PubMed/NCBI
18	Shijubo N, Uede T, Kon S, Maeda M, Segawa T, Imada A, Hirasawa M and Abe S: Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med. 160:1269–1273. 1999. View Article : Google Scholar : PubMed/NCBI
19	Donati V, Boldrini L, Dell'Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F and Fontanini G: Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res. 11:6459–6465. 2005. View Article : Google Scholar : PubMed/NCBI
20	Boldrini L, Donati V, Dell'Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F and Fontanini G: Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer. 93:453–457. 2005. View Article : Google Scholar : PubMed/NCBI
21	Le QT, Chen E, Salim A, et al: An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res. 12:1507–1514. 2006. View Article : Google Scholar : PubMed/NCBI
22	Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ and Gandara DR: SWOG Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol. 26:4771–4776. 2008. View Article : Google Scholar : PubMed/NCBI
23	Schneider S, Yochim J, Brabender J, Uchida K, Danenberg KD, Metzger R, Schneider PM, Salonga D, Hölscher AH and Danenberg PV: Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res. 10:1588–1596. 2004. View Article : Google Scholar : PubMed/NCBI
24	Takenaka M, Hanagiri T, Shinohara S, et al: Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non-small-cell lung cancer. Clin Lung Cancer. 14:288–294. 2013. View Article : Google Scholar : PubMed/NCBI
25	Isa S, Kawaguchi T, Teramukai S, et al: Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. J Thorac Oncol. 4:1104–1110. 2009. View Article : Google Scholar : PubMed/NCBI
26	Albain KS, Barlow WE, Shak S, et al: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, estrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11:55–65. 2010. View Article : Google Scholar : PubMed/NCBI
27	Lièvre A, Bachet JB, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 26:374–379. 2008. View Article : Google Scholar : PubMed/NCBI
28	Kratz JR, He J, Van Den Eeden SK, et al: A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet. 379:823–832. 2012. View Article : Google Scholar : PubMed/NCBI
29	Rangaswami H, Bulbule A and Kundu GC: Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 16:79–87. 2006. View Article : Google Scholar : PubMed/NCBI
30	Goparaju CM, Pass HI, Blasberg JD, Hirsch N and Donington JS: Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. J Thorac Oncol. 5:1516–1523. 2010. View Article : Google Scholar : PubMed/NCBI
31	Rahbari NN, Aigner M, Thorlund K, et al: Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 138:1714–1726. 2010. View Article : Google Scholar : PubMed/NCBI